CD274 and neoplasm with perivascular epithelioid cell differentiation: In another case, two courses of SBRT up to 30 Gy in 6 fractions coupled with the programmed death (PD)-1 inhibitor tislelizumab provided disease control for a metastatic pelvic PEComa with positive PD-L1 expression (64); utilization of the SBRT technique in conjunction with SIBs appears to permit dose escalation to overcome the inherent radioresistance of malignant PEComas while sparing normal tissues (65).